Efficacy and safety analysis of anlotinib in combination with immune checkpoint inhibitors for second-line and subsequent extensive-stage small-cell lung cancer / Xixi Ying ... [et al.]. Neoplasma Vol. 71, no. 3 (2024), s. 297-305